MANAGEMENT PRESENTATION - Monica Wallter, CEO - Lidds
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
MANAGEMENT PRESENTATION
Monica Wallter, CEO
monica.wallter@liddspharma.com
1
November 2018
Table of content
1. Introduction to LIDDS
2. NanoZolid® with 2-HOF – Prostate cancer
3. NanoZolid® with cytostatics (DTX)
4. NanoZolid® for immunotherapy (IO)
5. NanoZolid® with STING-agonist
6. NanoZolid® with TLR9 agonist
A. Appendix
2
Unique and patented technology platform
in brief
ONE PLATFORM PROJECTS
LIDDS is a Swedish-based pharmaceutical company developing
injectable drugs for cancer and other diseases based on our unique
proprietary NanoZolid® technology. NanoZolid® helps solve some of
Combined with anti-androgen
Liproca® Depot for treatment of localized
the main problems with the way drugs work in the body and which
prostate cancer
affect patient quality of life. Status: Phase IIb
NanoZolid® enables the controlled, long-term release of drugs for up
Combined with cytostatic
to six months. NanoZolid® can be combined with traditional small as
NanoZolid® combined with Docetaxel (DTX)
well as with larger molecules. Status: Phase I study started Q1 2019
LIDDS has licensing agreements where NanoZolid® is combined with
antiandrogens and in-house development in pre-clinical projects in Combined with TLR9-agonist
clinical phase for cytostatics and immunoactive agents. NanoZolid® combined with TLR9-agonists
Status: Pre-clinical full program ongoing
Founded 2003 Combined with STING-agonist
NanoZolid® combined with STING-agonists (STING)
Status: Pre-clinical full program ongoing
HQ Uppsala, Sweden
Employees ~10
Combined with immunotherapy
NanoZolid® combined with a range of IO agents in
development
Listing venue Nasdaq First North Status: Ongoing preclinical package
3
NanoZolid® is an innovative drug delivery platform
IDEAL DRUG DELIVERY PROPERTIES
▪ NanoZolid® is a safe, flexible and functional method of delivering drugs.
▪ NanoZolid® provides effective, controlled and tailor made release of drugs with small or larger size.
▪ NanoZolid® has a broad drug formulation capability and can be formulated with substances of very different
molecular characteristics.
▪ The NanoZolid® matrix with drug is reabsorbed completely in the tissue due to its water solubility.
THE CONTROLLED RELEASE OF DRUG COMPOUNDS CAN BE TAILORED TO THE NEEDS OF THE PATIENT, DISEASE AND DRUGS BEING USED:
The platform can be used for a wide range of applications
NanoZolid® has many applications and can be tailored to the needs of the patient, the disease being
treated and the drug formulations being used.
Intratumorally
NanoZolid® provides a high level of efficiency by allowing cancer drugs to be
injected directly into the tumor.
Controlled release results in higher local impact and reduced severe systematic
side effects for patients.
Subcutaneously
NanoZolid® can be injected subcutaneously allowing for sustained release of active
drugs over an extended period of time for systematic impact and improved
compliance.
✓ THE TECHNOLOGY IS CLINICALLY PROVEN WITH VALIDATED EFFECTS DURING 6 MONTHS IN PHASE II CLINICALS
5
Strong benefits for both patients and pharma industry
PATIENTS PHARMA INDUSTRY
Improved efficacy Improved products
‒ Higher drug effects in diseased area ‒ NanoZolid® enables higher efficiency, compliance and reduced
side effects
Less side effects Prolonged patent protection
‒ Minimal and controlled concentration of drug systemically – ‒ NanoZolid technology maintains competiveness with patents
improving Quality Of Life until 2037
‒ Opportunity for Life Cycle Management
Less injections Re-open closed projects
‒ The sustained and controlled drug release gives higher ‒ Previously closed projects due to severe side effect or too fast
compliance and Quality Of Life release of the drug can be re-opened
6
NanoZolid® – a clinically validated technology
A safe, flexible and functional method of delivering drugs as a long-acting depot
▪ Intratumoral drug delivery enables a high drug load and efficacy in cancer tumors
combined with small risks for systemic adverse effects - quality of life for patients
▪ Effectively reduces the number of treatments and adverse effects which in turn
reduces patient discomfort, improves compliance and reduces costs
NanoZolid® is formulated with APIs with different size & characteristics:
▪ Anti-androgens: 2-hydroxy-flutamide & other anti-androgen drugs
▪ Cytotoxic drugs: Docetaxel, Doxorubicin, Cisplatin, Temozolamide & other
cytostatics
▪ Immuno-active agents: STING-agonists, TLR- agonists, IDO1-inhibitors
▪ Hormones: i.e Testosterone
▪ Glucocorticoids
▪ Antihistamines
▪ Polypeptides
7Patent protection until year 2037
1
ANTI ANDROGENS – PROSTATECANCER
NZ-2-HOF
Liproca® Depot, 2-hydroxy-flutamide
2
CYTOTOXICS – SOLID TUMORS
NANOZOLID® NZ-DTX , NZ-DOX etc
PATENT PORTFOLIO Docetaxel, doxorubicin and other cytotoxic drugs
8 patent families 3
& 90 patents IMMUNO-ONCOLOGY
NZ-IO-STING, NZ-IO-TLR9, NZ-IO-003, NZ-IO-004
Immuno-active molecules
4
EXTERNAL PARTNERSHIP – NZ
A wide range of indications are possible
8LIDDS’ business model
1 2 3 4
PROVEN DRUG NANOZOLID® INNOVATIVE LICENSE
SUBSTANCE TECHNOLOGY PRODUCT AGREEMENTS
Off patent or new API Validated in Phase II Local injection Strategic partnerships
enables optimal Typically in pre-clinical phase or
product design Phase I/II
LIDDS’ business strategy is to use the NanoZolid® technology for three purposes: in-house drug development, for outlicensing to other
pharma companies for use in their development of new drugs, and as a tool for life cycle management of established medicines.
9Overview of current development pipeline
OUT-LICENSING &
PROJECT TARGET FEASIBILITY PRECLINICAL PHASE I / II PHASE IIb AGREEMENTS
In-house drug development
Out-licensed to China - Licensing
NZ-2-HOF Prostate cancer ✓ ✓ ✓ 2017-2019 to ROW during / after Phase IIb
NZ- DTX Malignant tumors ✓ ✓ ✓ Out-licensing after Phase I
Out-licensing after preclinical
NZ-IO- STING Malignant tumors ✓ ✓ phase
NZ-IO-TLR9 Malignant tumors ✓ ✓ Out-licensing after Phase I
NZ-IO-003-004 Malignant tumors ✓
NZ-DOX Malignant tumors ✓
NanoZolid® constitutes the bedrock for building a broad portfolio of pharmaceutical projects,
which diversifies risk and provides good prospects for future revenue
10Table of content
1. Introduction to LIDDS
2.
2. NanoZolid® with 2-HOF – Prostate cancer
3. NanoZolid® with cytostatics (DTX)
4. NanoZolid® for immunotherapy (IO)
5. NanoZolid® with STING-agonist
6. NanoZolid® with TLR9 agonist
A. Appendix
11NZ- 2-HOF
LIDDS treats prostate cancer
locally
▪ Clinical studies shows Liproca® Depot has enhanced
effects at higher doses, without the hormonal side
effects that are common with oral treatment.
▪ Phase I/II clinical trials with Liproca ®Depot is reported in
57 patients with good results on PSA biomarker, tumor
tissue and prostate volume
▪ Industrial scale production - NZ-2-HOF at Recipharm
▪ LPC-004 status- Safety and tolerability confirmed after
Part I - entered into Part II in Q3/18
▪ Phase IIb study ongoing – results in mid 2019
▪ Out-licensed to China
▪ Out-licensing to ROW during / after Phase IIb
12NZ- 2-HOF
Local treatment strategy
Traditional systematic treatment Treatment with LIDDS
ALL BODY EXPOSED LIDDS TARGETS ONLY THE ORGAN
Chemical castration & anti androgen therapy side LIDDS’ drug candidate is injected directly into the
effects: tumour
▪ Loss of libido & Erectile dysfunction ▪ Provides a pre-determined, controlled and long-term effect on
▪ Hot flushes the tumour
▪ Gynaecomastia and breast pain
▪ Increase in body fat & Muscle wasting
▪ Anemia
▪ Decrease in bone mineral density Side effects are fully avoided or significantly reduced
▪ Cognitive decline
13NZ- 2-HOF
PSA reduction %: LIDDS dose/effect prediction in Phase
Ilb study based on previous studies
n = 60 patients with local prostate cancer
LPC-002 (700mg) 6 months
LPC-0031 (900mg) 2 months
LPC-0032 (1,700mg) 2 months
LPC-004 (2,000mg) simulated
LPC-004 (4,000mg) simulated
14NZ- 2-HOF
The global prostate cancer drug market is
estimated to ≥ 8 billion USD in 2022
1,300,000 Global prostate cancer market
Patients diagnosed per year1
$8.3bn in 20234
Every fifth man
Will be diagnosed 20302
5%
250,000 patient share
Liproca® Depot yearly sales:
Dies every year3 ≥ $1,000m
15 Source: (1) World Cancer Research Fund, 2018, (2) Cancer Research UK, (3) Prostate Smart, (4) PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023.Table of content
1. Introduction to LIDDS
2. NanoZolid® with 2-HOF – Prostate cancer
3.
3. NanoZolid® with cytostatics (DTX)
4. NanoZolid® for immunotherapy (IO)
5. NanoZolid® with STING-agonist
6. NanoZolid® with TLR9 agonist
A. Appendix
16NZ- DTX
Lung cancer and solid tumors
Preclinical study shows that NZ-DTX is as
efficient as systemic docetaxel in reducing
tumor growth but with far less side effects
▪ Docetaxel is a commonly used chemotherapy: Breast,
head and neck, gastric, prostate and non small cell lung
cancer (NSCLC).
▪ Monotherapy or in combination with different drugs to
optimize effects:
- Neoadjuvant NZ-DTX before surgery/radiation
- Treatment at diagnosis of tumor
- Palliative therapy
- Combination with systemic drugs, e.g. cytostatics / I-O
- Phase I Study started 2019, Scandinavian sites
17NZ- DTX
Promising potential of a focal treatment with
docetaxel in non-small cell lung cancer & solid tumors
Lung cancer 310,000
230,000 Diagnosed in
$37bn Diagnosed in US2 EU283
global market1
CAGR of
>13%
until 20231
>540,000 individuals are diagnosed with lung cancer in the EU28 and the US
18 Source: (1) Lung Cancer Market Research Report – Global Forecast to 2023; (2) American Cancer Society, 2018; (3) Lung Cancer Europe, GLOBOCAN 2012.Table of content
1. Introduction to LIDDS
2. NanoZolid® with 2-HOF – Prostate cancer
3. NanoZolid® with cytostatics (DTX)
4.
4. NanoZolid® for immunotherapy (IO)
5. NanoZolid® with STING-agonist
6. NanoZolid® with TLR9 agonist
A. Appendix
19NZ-IO
Immuno Oncology (IO) – a major
opportunity for LIDDS
Providing an intratumoral sustained release
immuno-modulating treatment that increases
response rates while minimizing side-effects
Several preclinical projects ongoing, including
NZ-STING and NZ-TLR9
20NZ-IO
Intratumoral Immunotherapy: Acting locally for
systemic efficacy
INTRATUMORAL INJECTION
Local treatment Distal effects
Intratumoral injection with Systemic anti-tumor
Nanozolid formulated drug immunity in non-injected
to stimulate immunity tumors
21NZ-IO
Providing a local immuno-modulating treatment that
increases response rates while minimizing side-effects
COMBINATION THERAPY
IS THE FUTURE
“Emphasis on combination strategies
continues to resonate throughout the
scientific community and has been
highlighted at several recent
PERCENTAGE SURVIVAL
conferences. During Immunotherapy
Immunotherapy World (January 2017), it was even
combination stated that the field would ultimately
Increased response
rates and long-term move “entirely” to combination
survival therapies.”
- Erin Newburn MS, PhD
Immunotherapy
monotherapy
The future of these drugs is in
combination strategies […] And, most
Increased long-
Traditional of the data that are leaking out of
term survival therapies ASCO and other meetings are looking
at combinations.
- Benjamin P. Levy, Clinical Director of
Control Medical Oncology at Kimmel Cancer Centre
TIME FROM TREATMENT
22NZ-IO
Intratumoral Immunotherapy:
Leveraging the potential with NanoZolid®
23NZ-IO
Intratumoral Immunotherapy
▪ Local, intratumoral immunotherapy enables the use of potent immune
stimulating agents (e.g. STING agonists, TLR-agonists) that can be
combined with check point inhibitors or other IO drugs
▪ Local immune stimulation can induce systemic anti-tumor immunity
▪ Possibility to turn “cold tumors” into “hot tumors” that can respond to
checkpoint inhibition treatment
▪ NanoZolid ® formulated local acting immunotherapies offers greater
treatment options, higher efficacy, increased patient friendliness and
greater healthcare penetration
▪ Enables treatment of deep-lying tumors which can be more
immunologically representative of primary and metastasizing tumors
(e.g. lung, brain, colon, prostate, gastric cancers etc.)
▪ NanoZolid ® technology enables the potential of intratumoral
immuno-therapy by providing a practical, efficacious and patient-
friendly drug delivery technology
24Table of content
1. Introduction to LIDDS
2. NanoZolid® with 2-HOF – Prostate cancer
3. NanoZolid® with cytostatics (DTX)
4. NanoZolid® for immunotherapy (IO)
5.
5. NanoZolid® with STING-agonist
6. NanoZolid® with TLR9 agonist
A. Appendix
25NZ-STING
NanoZolid® - STING (NZ-STING)
STING - Stimulator of interferon genes
▪ Highly promising agent for immune stimulation
▪ Local activation of STING in tumors leads to potent tumor regression
and systemic immunity
▪ Activators of STING have the potential to make more cancers respond
to immunotherapy
▪ Actively pursued by BMS, Merck, GSK, Novartis and others
▪ STING must be administered intratumorally due to severe systemic
side effects
26NZ-STING
Working hypothesis
▪ STING agonist treatment is effective when administered in the right
way
▪ For better safety:
• A slow (and controlled) intratumoral release resulting in low risk
for systemic side effects
• Fewer injections avoid risks for complications
▪ NanoZolid formulations makes STING agonists practical for treatment:
• Single injection active up to several months
• Especially important for tumors not suitable for multiple injections
• NanoZolid depot is visible with x-ray and ultra sound equipment to
confirm correct injection
• Reduced cost for treating hospitals
• Better patient compliance and convenience
▪ Major commercial opportunity
27NZ-STING
NZ-STING- extensive preclinical programme
Syngeneic preclinical animal models were used at a qualified
European CRO:
A single NZ-STING injection was equal or better to reduce tumor
growth versus three repeated standard STING injections
▪ Verified efficacy in different syngeneic models
▪ Safe and well tolerated
▪ Potential to leverage NanoZolid® technology in highly
competitive and promising field
▪ Patent application submitted for NZ-STING
28Table of content
1. Introduction to LIDDS
2. NanoZolid® with 2-HOF – Prostate cancer
3. NanoZolid® with cytostatics (DTX)
4. NanoZolid® for immunotherapy (IO)
5. NanoZolid® with STING-agonist
6.
6. NanoZolid® with TLR9 agonist
A. Appendix
29NZ-IO-TLR9
TLR9 agonist project ongoing and plan for Phase I
▪ LIDDS has performed pre-clinical studies with promising results using a
TLR9 agonist formulated with NanoZolid®
▪ A preclinical programme is ongoing to broaden the results obtained to
date
▪ Currently preparing for a Phase I clinical trial using NanoZolid®
combined with a TLR9 agonist
▪ Planned start for clinical Phase I trial in 2020
▪ Major commercial opportunity
▪ The most relevant target cancers for the TLR9 project are head
and neck cancer, prostate cancer and lymphomas. These cancers
are diagnosed in around 2 million patients each year.
30NZ-IO-
STING/TLR9
Local immunotherapy with NanoZolid® provides
several advantages vs standard injections
Standard STING/TLR9-injection NanoZolid STING/TLR9 depot
ˣ Frequent injections ✓Up to once every 3 to 6 months
ˣ Superficial tumors Vs. ✓Superficial and deep-lying
tumors
ˣ Limited patient population eligible
✓Greater options regarding
treatment and including poor
ˣ Limited tumor residence time
status patients
ˣ Includes high costs and resources ✓Long-term immune stimulation
in specialized hospitals
✓Less costs and resources needed
31Significant value inflection points ahead
EXPECTED Q1 2019 – Q2 2019 EXPECTED Q3 2019 – Q4 2019
▪ Start of Phase I study NZ- DTX-001 ▪ Concluding the Phase IIb study
✓ and first patient in
▪ Update on NZ-DTX-001
▪ Preclinical research program NZ-IO-
STING ▪ Update of NZ-IO projects
▪ Preclinical studies NZ-IO- 002-004 ▪ New NZ-projects
▪ Status update of NZ-2HOF, LPC-004 EXPECTED 2020
▪ Organization Expansion ▪ Listing of the company’s shares on
Nasdaq Stockholm’s Main Market
32Table of content
1. Introduction to LIDDS
2. NanoZolid® with 2-HOF – Prostate cancer
3. NanoZolid® with cytostatics (DTX)
4. NanoZolid® for immunotherapy (IO)
5. NanoZolid® with STING-agonist
6. NanoZolid® with TLR9 agonist
A.
A. Appendix
33A. APPENDIX
Shareholder list
Shareholders as per 31 December 2018 Number of shares Capital Votes
Wikow Ventures AB (Lars Wikander) 1,955,048 8.48 % 8.46 %
Daniel Lifveredson through companies 1,914,393 8.30 % 7.63 %
Nyenburgh Holding B.V. 1,521,355 6.60 % 7.01 %
Bengt Sporre 923,567 4.01 % 4.01 %
Recipharm Venture Fund AB 714,285 3.10 % 3.10 %
Gunvald Berger 571,258 2.48 % 2.48 %
BWG Invest Sàrl (William Gunnarsson) 531,000 2.30 % 2.32 %
Henry Dunkers Donationsfond & Stiftelser 412,314 1.79 % 2.30 %
Hans Lennernäs with company 373,268 1.62 % 1.64 %
Arena Invest AB (Roberth Emanuelsson) 318,471 1.38 % 1.38 %
Sub total 9,234,959 40.06 % 40.06 %
Others 13,816,229 59.94 % 59.94 %
Total 23,051,188 100.0 % 100.0 %
SEK
>200 million
Since LIDDS was founded in 2003, more than SEK 200 million has been invested into the company and the development
of the NanoZolid® technology platform.
34A. APPENDIX
Income statement
(TSEK) Oct-Dec 2018 Oct-Dec 2017 Jan-Dec 2018 Jan-Dec 2017
Other sales 0 434 7,763 1,029
Gross income 0 434 7,763 1,029
Other external expenses -2,383 -1,561 -6,916 -4,588
Personnel expenses -994 -1,085 -3,150 -3,124
Impairment of intangible assets -1,577 0 -1,577 0
Total costs -4,954 -2,646 -11,643 -7,712
Operating profit -4,954 -2,212 -3,880 -6,683
Financial items 14 1 133 14
Profit for the period -4,940 -2,211 -3,747 -6,669
35A. APPENDIX
Balance sheet
(TSEK) 2018-12-31 2017-12-31
ASSETS
Fixed assets
Capitalized development costs 123,002 101,091
Patent 12,746 13,189
Total intangible assets 135,748 114,280
Total tangible assets 50 0
Total fixed assets 135,798 114,280
Current assets
Short-term receivables 1,439 1,245
Cash and cash equivalents 26,139 15,286
Total current assets 27,578 16,531
Total assets 163,376 130,811
EQUITY AND LIABILITIES
Equity 158,517 127,250
Short-term liabilities 4,859 3,561
Total equity and liabilities 163,376 130,811
36A. APPENDIX
Cash flow statement
(TSEK) Oct-Dec 2018 Oct-Dec 2017 Jan-Dec 2018 Jan-Dec 2017
Cash flow from the operating business -4,297 -1,345 -1,066 -10,715
Cash flow form investment activities -7,097 -4,066 -23,096 -14,079
Cash flow from financing activities 0 1,000 35,015 21,399
Cash flow for the period -11,394 -4,411 10,853 -3,395
Cash position at the beginning of the period 37,533 19,697 15,286 18,681
Cash position at the end of the period 26,139 15,286 26,139 15,286
37A. APPENDIX
Board of directors
JAN TÖRNELL MARIA FORSS
Chairman of the Board since 2015 Board member since 2015
Holdings: 33,142 shares, 250,000 warrants Holdings: 18,100 shares, 150,000 warrants
15 years of experience in executive roles in the pharmaceutical industry in Master’s degree in Economics from the School of Business, Economics and
various countries. Professor with medical background. CEO of Oncorena AB Law and Concordia University, Montreal. Active as VP Business Development
and AB Innoext. Former Vice President of Global Strategy for AstraZeneca & Global Marketing at the Swedish listed company Vitrolife since 2012. Maria
Oncology & Infection. Professor of Physiology at the Sahlgrenska Academy. Forss has for 20 years worked with product development, business
Chairman of Glactone Pharma AB and board member of Diaprost AB. Partners development and marketing of pharmaceutical products in global roles at
in P.U.L.S. and member of the investment committee. Born 1960. AstraZeneca, as well as in the virtual company DuoCort, where she as CEO and
project managers had been instructed to take a new drug from clinical trials
to regulatory approval and sales of the company. She has experience in
product development of medicines from early phase to commercialization,
and from several board positions in the pharmaceutical and medical
DANIEL LIFVEREDSON technology companies. Born 1972.
Board member since 2017
Holdings: 1,759,492 shares, 200,000 warrants
M.Sc. in Engineering, Industrial Economy, Chalmers tekniska högskola in
Gothenburg. CEO and owner of Excore AB, specialized in counseling in
connection with corporate transactions in the segment of medium-sized
companies. Long experience in international business. Daniel Lifveredson is ANDERS BJARTELL
engaged as a partner in several companies. Born 1976. Board member since 2015
Holdings: 18,100 shares, 150,000 warrants
Professor and chief of urology at Skåne University Hospital since 2006. PhD in
Medical cell research. European specialist degree in Urology. Visiting
investigator at Memorial Sloan-Kettering Cancer Center in New York, 2005-
INGALILL FORSLUND LARSSON 2007. Associate Editor of European Urology, 2005-2012. Responsible for
Board member since 2015 clinical trials in prostate cancer at the urology clinic SUS Malmö since 2007.
Holdings: 10,000 shares, 125,000 warrants National Principal Investigator for several new drugs for prostate cancer in
recent years. Research group leader for urological cancer research at the
Economist with specialization in Marketing from the University of Uppsala. Leg. Institute for Translational Medicine at Lund University. Published over 200
Midwife. Many years of sales and marketing responsibility in the original scientific articles. H-index 39. Have experience in board work in
pharmaceutical industry, incl. business responsibility for Urology, Global European Urology, foundations and life science. Born 1959.
Marketing at Ferring Pharmaceuticals. several commercial roles at AstraZeneca
incl. responsible for a number of product launches. Senior Consultant at Lisberg
Executive Search and Boyden International. CEO of a private real estate and
consulting company. Board experience from several life science companies.
Born 1954.
38A. APPENDIX
Senior executives and management
MONICA WALLTER
CEO
Holdings: 20,019 shares, 125,000 warrants MARTIN JOHANSSON
International Diploma in Marketing & Economics from University of Lund, Head of preclinical R&D in immunotherapy
Sweden. Former CEO of Ellen AB (publ) from 2008 to 2014 and CEO of Probi Holdings: 500 shares, 25,000 warrants
AB (publ) 2000-2003. Senior international management positions in
Pharmacia between 1986-1995. Heading several business areas as Global M.Sc. chemical engineering Lund University, Ph.D. and associate professor in
Category Director at Pharmacia & Upjohn during 1996-2000. organic chemistry at Lund University. 17 years of experience in medicinal
chemistry and preclinical research and development. Formed Chief Scientific
Officer with Respiratorius and senior research scientist at AstraZeneca
Discovery R&D.. Project manager for Glactone Pharma.
BENGT NORVIK
CFO
Holdings: 33,274 shares, 25,000 warrants
Accountant from the University of Uppsala. Former CFO of Know IT AB (publ), MARKUS THOR
Pargon AB and AB Upnod. Bengt runs his own business Markett Head of Business Development
Affärsutveckling AB, which provides consulting services in economics and Holdings: 0 shares, 0 warrants
finance. Bengt has experience from both listed as start-ups in Life Science, IT
industry and commerce. MBA from Stockholm School of Economics and M.Sc. in Chemistry from Umeå
University. 25 Years of experience in the pharmaceutical industry with
positions within business development and R&D including Vice President &
STEFAN GRUDÉN Head of Business Development at Biovitrum AB, Chief Business Officer at
Kancera AB and Senior Scientist at Pharmacia.
Director of pharmaceutical R&D
Holdings: 500 shares, 25,000 warrants
Pharmacists, M.Sc. Pharm., From Uppsala University. 17 years experience in
pharmaceutical research and development, including 15 years in senior services
and Pharmacy Manager both Galenica and Orexo. Participated in the CHARLOTTA GAUFFIN
development of over 50 projects, of which more than a third have been upscaled.
Head of Clinical Trial Management
Holdings: 0 shares, 0 warrants
NIKLAS AXÉN Master of Science M.Sc. and Ph.D. in organic chemistry from Uppsala University.
Director of Biomaterials & Devices About 20 years of experience in the pharmaceutical industry, within research
Holdings: 70,000 shares, 25,000 warrants and clinical development. Has held senior clinical project management
positions at Quintiles and Q-Med/Galderma, with experience from a range of
M.Sc. Engineering Physics at Uppsala University, PhD and Associate Professor indications within drug and medical device development.
of Materials Science at Uppsala University. Niklas Axen has previously worked
in product development at De Beers and Hemapure, and has been in charge
of R & D including Cerbio AB, Doxa AB and AB OrtoWay.
39A. APPENDIX
Overview of LIDDS’ patent portfolio
PATENT PATENT US EU REST OF THE WORLD
1 / 2004 Bioceramic compositions Approved Approved Not filed
Aus, Can, Chi, Jap, Mex, Russ, S Kor,
2 / 2006 Method to treat prostate cancer Approved Approved
Nor, Afr, Isr, Ind,
Aus, Can, Chi, HK, Jap, Mex, Russ, S Kor,
3 / 2007 Slow local drug release Approved Approved
Isr, S. Afr, Ind,
Aus, Can, Chi, Russ, Isr, Jap, Mex, S
4 / 2009 Mixing tool suspensions Approved Approved
Korea, Ind, S. Afr
Aus, Can, Russ, Jap, HK, Mex, S.Kor, Ind,
5 / 2009 Steering of curing Approved Approved
Isr, S. Afr
6 / 2016 Manufacturing process Approved Approved -
7 / 2017 NanoZolid + STING - Filed -
40Thank you!
Monica Wallter, CEO
LIDDS AB
monica.wallter@liddspharma.com
41You can also read
